Cyclerion Therapeutics, Inc. (CYCN): Price and Financial Metrics

Cyclerion Therapeutics, Inc. (CYCN): $3.11

0.18 (+6.14%)

POWR Rating

Component Grades








Add CYCN to Watchlist
Sign Up

Industry: Biotech




#103 of 439

in industry

CYCN Price/Volume Stats

Current price $3.11 52-week high $13.78
Prev. close $2.93 52-week low $1.75
Day low $2.99 Volume 4,800
Day high $3.18 Avg. volume 3,416
50-day MA $3.36 Dividend yield N/A
200-day MA $3.55 Market Cap 7.60M

CYCN Stock Price Chart Interactive Chart >

CYCN Stock Summary

  • CYCN has a higher market value than just 4.32% of US stocks; more precisely, its current market capitalization is $8,239,974.
  • For CYCN, its debt to operating expenses ratio is greater than that reported by just 0.22% of US equities we're observing.
  • As for revenue growth, note that CYCN's revenue has grown -60.77% over the past 12 months; that beats the revenue growth of merely 3.65% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CYCLERION THERAPEUTICS INC are SMSI, SPOK, LQDT, INSG, and BHIL.
  • Visit CYCN's SEC page to see the company's official filings. To visit the company's web site, go to

CYCN Valuation Summary

  • CYCN's EV/EBIT ratio is 0.1; this is 99.32% lower than that of the median Healthcare stock.
  • Over the past 58 months, CYCN's EV/EBIT ratio has gone up 1.8.

Below are key valuation metrics over time for CYCN.

Stock Date P/S P/B P/E EV/EBIT
CYCN 2023-12-29 13.5 0.6 -0.8 0.1
CYCN 2023-12-28 16.0 0.8 -0.9 -0.1
CYCN 2023-12-27 16.9 0.8 -1.0 -0.1
CYCN 2023-12-26 16.8 0.8 -0.9 -0.1
CYCN 2023-12-22 17.3 0.8 -1.0 -0.1
CYCN 2023-12-21 16.4 0.8 -0.9 -0.1

CYCN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CYCN has a Quality Grade of C, ranking ahead of 48.21% of graded US stocks.
  • CYCN's asset turnover comes in at 0.034 -- ranking 346th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows CYCN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.034 1 -0.991
2021-03-31 0.011 1 -0.741
2020-12-31 0.018 1 -0.770
2020-09-30 0.025 1 -0.733
2020-06-30 0.028 1 -0.734
2020-03-31 0.029 1 -0.788

CYCN Price Target

For more insight on analysts targets of CYCN, see our CYCN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.00 Average Broker Recommendation 1.5 (Moderate Buy)

Cyclerion Therapeutics, Inc. (CYCN) Company Bio

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CYCN Latest News Stream

Event/Time News Detail
Loading, please wait...

CYCN Latest Social Stream

Loading social stream, please wait...

View Full CYCN Social Stream

Latest CYCN News From Around the Web

Below are the latest news stories about CYCLERION THERAPEUTICS INC that investors may wish to consider to help them evaluate CYCN as an investment opportunity.

Cyclerion Appoints Regina Graul, Ph.D., as President

– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for

Yahoo | December 4, 2023

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence at Polaris Partners with a track record of launching successful companies CAMBRIDGE, Mass., Nov. 30, 2023 (G

Yahoo | November 30, 2023

Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses

Insiders who bought US$1.95m worth of Cyclerion Therapeutics, Inc.'s ( NASDAQ:CYCN ) stock at an average buy price of...

Yahoo | November 28, 2023

The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets

Peter Hecht, the co-founder and CEO of embattled biotech Cyclerion Therapeutics Inc. (Nasdaq: CYCN), is heading up a new startup that's effectively a life raft for Cyclerion's research. Elsewhere in the Petri Dish: a $1 billion deal for Pfizer gene therapies, a succession plan for a founder-led biotech organization, and a new Longwood Fund spinout with assets from GSK.

Yahoo | August 3, 2023

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved Therapies, Leveraging Extensive Preclinical and Clinical Data Generated by Cyclerion – CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Tisento Therapeutics, Inc. today announced the closing of the previously disclosed asset purchase agreement

Yahoo | July 31, 2023

Read More 'CYCN' Stories Here

CYCN Price Returns

1-mo 7.33%
3-mo 42.66%
6-mo -12.89%
1-year -76.11%
3-year -95.95%
5-year N/A
YTD -7.16%
2023 -74.47%
2022 -61.85%
2021 -43.79%
2020 12.50%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!